Eyal Neria
individual
About
Eyal Neria is an Israeli biotech executive known publicly as CEO of Mitoconix Bio, a company developing therapies for Huntington's disease and other neurodegenerative disorders by targeting mitochondrial dysfunction. Earlier, he served as VP R&D, Planning and Control at Compugen and was a director of Neviah Genomics on behalf of Compugen. The available evidence points to an operator/scientific leadership profile rather than an investor or fund manager.
Areas of interest
biotechneurodegenerationhuntington's diseaseparkinson's diseasemitochondrial biologydrug development